RECOVERable: Mental Health and Addiction Experts Answer Your Questions
Jul 30, 2026 · 1 hr 3 min · 12 segments
Can psilocybin and ibogaine truly cure depression and addiction, or are the risks being ignored? Find mental health and addiction treatment near you: https://recovery.com/ In Part 2 of this episode…
Chantel ThomasGuestTerri McGuireHost
Well, I've had the privilege to work at, uh, the University of Wisconsin-Madison, um, alongside of the Protea Lab and the, within the School of Pharmacy on various different clinical trials, um, starting with the high-dose psilocybin trial pharmacokinetic study, which is basically like a physical safety study of higher dose psilocybin to demonstrate its physical safety.

I've had the opportunity to work on depression trials with psilocybin, um, both in the room, but also providing support to facilitators across various sites in their training and their ongoing consultation and supervision during those trials.

And I've also had the privilege of working on, um, a number of trials targeting, uh, folks with substance use disorders.

So it's been really interesting looking at depression indications versus those for substance use disorders.

Um, and um, it's been fascinating what I've learned over time, you know, having done this for close to 13 years now and appreciated some of the nuances of what it looks like and how it looks differently.

And then lastly, I'm involved in a study right now for low wellbeing for, um, psilocybin for individuals at the University of Wisconsin-Madison, which is still actively recruiting.

And that is, um, that's a study called ENHANCE, and it's looking at using psilocybin alongside of vagal nerve stimulation to see if it has an impact on how persisting the effects are for individuals.

Well, I've had the privilege to work at, uh, the University of Wisconsin-Madison, um, alongside of the Protea Lab and the, within the School of Pharmacy on various different clinical trials, um, starting with the high-dose psilocybin trial pharmacokinetic study, which is basically like a physical safety study of higher dose psilocybin to demonstrate its physical safety.

I've had the opportunity to work on depression trials with psilocybin, um, both in the room, but also providing support to facilitators across various sites in their training and their ongoing consultation and supervision during those trials.

And I've also had the privilege of working on, um, a number of trials targeting, uh, folks with substance use disorders.

So it's been really interesting looking at depression indications versus those for substance use disorders.

Um, and um, it's been fascinating what I've learned over time, you know, having done this for close to 13 years now and appreciated some of the nuances of what it looks like and how it looks differently.

And then lastly, I'm involved in a study right now for low wellbeing for, um, psilocybin for individuals at the University of Wisconsin-Madison, which is still actively recruiting.

And that is, um, that's a study called ENHANCE, and it's looking at using psilocybin alongside of vagal nerve stimulation to see if it has an impact on how persisting the effects are for individuals.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.